Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Precision Oncology in Older Cancer Patients: A Single-Center Experience.
Petitat-Berli M, Knufinke M, Voegeli M, Sonderegger M, Seifert B, Chiru ED, Haeuptle P, Van't Walderveen L, Rosenberg R, Burri E, Subotic S, Schwab FD, Dougoud-Chauvin V, Unger H, Mertz K, Tahan L, Vetter M. Petitat-Berli M, et al. Among authors: voegeli m. Int J Mol Sci. 2024 Oct 21;25(20):11322. doi: 10.3390/ijms252011322. Int J Mol Sci. 2024. PMID: 39457104 Free PMC article.
Y90 -Ibritumomab tiuxetan (Y90 -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05).
Voegeli M, Rondeau S, Berardi Vilei S, Lerch E, Wannesson L, Pabst T, Rentschler J, Bargetzi M, Jost L, Ketterer N, Bischof Delaloye A, Ghielmini M. Voegeli M, et al. Hematol Oncol. 2017 Dec;35(4):576-583. doi: 10.1002/hon.2348. Epub 2016 Sep 28. Hematol Oncol. 2017. PMID: 27677906 Clinical Trial.
Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland.
Moccia AA, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Lang N, Mey U, Mingrone W, Novak U, Pfleger C, Richter P, Rütti M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Hitz F. Moccia AA, et al. Among authors: voegeli m. Hematol Oncol. 2021 Apr;39(2):196-204. doi: 10.1002/hon.2830. Epub 2020 Dec 23. Hematol Oncol. 2021. PMID: 33300135
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. Among authors: voegeli m. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
[How do patients experience nights in the hospital?].
Leuenberger F, Voegeli M, Wingeier M. Leuenberger F, et al. Among authors: voegeli m. Krankenpfl Soins Infirm. 1983 Apr;(4):30-2. Krankenpfl Soins Infirm. 1983. PMID: 6304400 German. No abstract available.